⌘K
Loading ticker…
Ensysce Biosciences, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Ensysce Biosciences, Inc. Common Stock (ENSC) has a 3-month relative strength percentile of 6 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 27. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 9.9%, relative volume 1.89×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
6 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
ENSC is in a stage 4 downtrend, week 10. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -8.6% / -71.6%.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
ENSC appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $7K notional.
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $7K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ENSC Jan avg: 2.38% median: -11.12% win: 25% σ: 34.15% n: 4 2022-04-12 → 2026-05-29 | ENSC Feb avg: -27.08% median: -25.86% win: 0% σ: 12.14% n: 4 2022-04-12 → 2026-05-29 | ENSC Mar avg: -24.63% median: -16.21% win: 0% σ: 18.64% n: 4 2022-04-12 → 2026-05-29 | ENSC Apr avg: -13.40% median: -22.84% win: 20% σ: 19.84% n: 5 2022-04-12 → 2026-05-29 | ENSC May avg: -27.90% median: -26.49% win: 0% σ: 17.10% n: 5 2022-04-12 → 2026-05-29 | ENSC Jun avg: 4.84% median: -5.73% win: 50% σ: 34.83% n: 4 2022-04-12 → 2026-05-29 (current) | ENSC Jul avg: -11.41% median: -8.72% win: 25% σ: 22.03% n: 4 2022-04-12 → 2026-05-29 | ENSC Aug avg: -9.71% median: -10.43% win: 25% σ: 7.52% n: 4 2022-04-12 → 2026-05-29 | ENSC Sep avg: -25.09% median: -32.32% win: 25% σ: 27.43% n: 4 2022-04-12 → 2026-05-29 | ENSC Oct avg: 18.46% median: -16.45% win: 25% σ: 81.70% n: 4 2022-04-12 → 2026-05-29 | ENSC Nov avg: -4.88% median: -12.23% win: 25% σ: 19.41% n: 4 2022-04-12 → 2026-05-29 | ENSC Dec avg: -29.83% median: -27.52% win: 25% σ: 38.26% n: 4 2022-04-12 → 2026-05-29 |